Lung disease often develops silently, and early signs are easily missed until symptoms become severe and harder to treat. Recognizing these respiratory symptoms sooner can significantly change patient outcomes. AstraZeneca Switzerland is committed to making lung health a priority by raising awareness of risk factors, encouraging early medical check-ups, and building clinical partnerships that strengthen respiratory care across the country.
Expert perspectives on lung health
Hear from a patient organisation and a healthcare professional about
lung health and ongoing support.
Prof. Dr. med. Daniel Franzen
Head of Internal Medicine and Co-Chief of Pneumology Spital Uster
Recognising lung disease and improving care
- Why earlier diagnosis matters
- The value of coordinated care and follow-up
- Helping people manage their condition over time
Lung health is not a niche topic. It is about prevention, early detection and the chance to live longer and, above all, healthier.
Joel Kaiser
Technical Specialist, CPAP and Home Ventilation
Deputy Head of Home Therapy, Lungenliga beider Basel
Understanding symptoms and finding support
- Why people may put off seeking help
- How clear information can build understanding
- Support available through the Lungenliga
Symptoms become part of everyday life before those affected even notice that something has changed.
Lung Cancer
Lung cancer remains one of the most severe cancer diagnoses in Switzerland, primarily because it is frequently detected in advanced stages. Early-stage lung cancer (TNM Stage I and Stage II; localised, potentially resectable) often presents no symptoms, limiting treatment options once symptoms appear. While smoking is the primary risk factor, a significant number of cases occur in non-smokers. This highlights the critical importance of early lung cancer detection, which substantially improves treatment success and survival rates.1-4
4,400-4,500
80-90%
~70
Only 25-30%
20-28%
COPD
Chronic Obstructive Pulmonary Disease (COPD) is a widespread, progressive condition characterised by irreversible airway obstruction. COPD develops gradually over time, with smoking and air pollution being the most common causes.1,2
~400k
40-55
90%
Up to 847
10k
Asthma
Asthma is a chronic inflammatory disease of the airways characterised by shortness of breath, wheezing, coughing, and chest tightness. When severe or poorly controlled, asthma can significantly impair a patient's quality of life.1
5.4%
5-10%
88
45%
84%
Our stories of progress in cancer care
For more information on AstraZeneca’s therapeutic areas - including disease risks, symptoms, early diagnosis and treatment options - visit myastrazeneca.ch
References
Lung Cancer:
- Galli F, Rohrmann S, Lorez M; NICER Working Group. Lung cancer survival in Switzerland by histology, TNM stage and age at diagnosis. Swiss Cancer Bulletin. 2019;39(1):69-73.
- Bundesamt für Statistik. Schweizerischer Krebsbericht 2021. https://www.bfs.admin.ch/bfs/en/home/news/whats-new.assetdetail.19305696.html (Accessed 10.2026).
- Krebsliga Schweiz. Was ist Lungenkrebs? https://www.krebsliga.ch/ueber-krebs/krebsarten/lungenkrebs-bronchialkarzinom/was-ist-lungenkrebs/ (Accessed 10.2026).
- Rosenfluh Verlag. Onkologie. https://www.rosenfluh.ch/media/onkologie/2025/04/Umweltfaktoren-Strahlung-Genetik-Update-Lungenkrebs-bei-Nichtrauchern.pdf (Accessed 10.2026).
COPD:
- Lungenliga Schweiz. COPD – Chronisch obstruktive Lungenkrankheit: Ursachen, Symptome und Behandlung. https://www.lungenliga.ch/krankheiten-therapien/copd (Accessed 10.2026).
- Bridevaux PO, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland (SAPALDIA). Eur Respir J. 2010;36(6):1259–1269.
- Medinfo-Verlag. Pilot integrierter Patientenpfad COPD. https://www.medinfo-verlag.ch/pilot-integrierter-patientenpfad-copd/ (Accessed 10.2026).
- Lungenliga Schweiz. COPD – Früh erkennen – wirksam behandeln. https://lungenliga.rokka.io/dynamic/noop/60292cb841d085e1ec2a17124b4d0b72c71b3069/10031006d-copd.pdf (Accessed 10.2026).
- WHO / Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2023. Seattle: Institute for Health Metrics and Evaluation (IHME); 2025. https://www.healthdata.org/research-analysis/library/global-burden-disease-2023-findings-gbd-2023-study (Accessed 10.2026).
- Klinik Hirslanden. COPD – Frühzeitige Diagnose und Therapie verhindert Fortschreiten der Krankheit. Medienmitteilung; 2024. https://www.hirslanden.ch/de/klinik-hirslanden/news-und-medien/medienmitteilungen/copd-diagnose-und-therapie.html (Accessed 10.2026).
- Terzikhan N, Verhamme KM, Hofman A, et al. Prevalence and incidence of COPD in smokers and non-smokers: the Rotterdam Study. Eur J Epidemiol. 2016;31(8):785–792.
- Kamal R, Srivastava AK, Kesavachandran CN. Meta-analysis approach to study the prevalence of chronic obstructive pulmonary disease among current, former and non-smokers. Toxicol Rep. 2015;2:1064–1074.
- Bukanova-Berend D, Campbell-James T, Vogel J. Hospitalizations and inpatient resource consumption of patients suffering from chronic disease - Past trend and forecast for Switzerland. BMC Health Serv Res. 2025;25(1):1514. Published 2025 Nov 24. doi:10.1186/s12913-025-13687-5.
- Gouveia A, et al. Potentially Avoidable Hospitalizations by Asthma and COPD in Switzerland from 1998 to 2018: A Cross-Sectional Study. Healthcare (Basel). 2023;11(9):1229.
Asthma:
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention, 2026. Updated May 2026. Available from: https://www.ginasthma.org (Accessed 10.2026).
- Schweizerisches Gesundheitsobservatorium (Obsan). Chronische Atemwegserkrankungen bei Personen ab 15 Jahren. Indikator des nationalen Monitorings nichtübertragbarer Krankheiten (MONAM). Neuchâtel: Obsan. https://ind.obsan.admin.ch/indicator/monam/atemwegserkrankungen-alter-15 (Accessed 10.2026).
- Hekking PPW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902.
- Bundesamt für Statistik (BFS). Sterbefälle und Sterbeziffern wichtiger Todesursachen, nach Alter, Frauen/Männer. Neuchâtel: BFS; 2024. https://www.bfs.admin.ch/asset/de/je-d-14.03.04.01.02 (Accessed 10.2026).
- Jaun F, et al. Characteristics of Severe Asthma Patients and Predictors of Asthma Control in the Swiss Severe Asthma Registry. Respiration. 2023;102(11):944–955.
- Heaney LG, Perez de Llano L, Al-Ahmad M, et al. Eosinophilic and Noneosinophilic Asthma: An Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. Chest. 2021;160(3):814–830.
Veeva ID: CH-14016
Date of preparation: November 2026